MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer

Lung Cancer

Volumn 83, Issue 2, 2014, Pages 146-153

  Li, Bing ^b   Ren, Shengxiang ^b   Li, Xuefei ^b   Wang, Yongsheng ^a   Garfield, David ^c   Zhou, Songwen ^a   Chen, Xiaoxia ^a   Su, Chunxia ^a   Chen, Mo ^a   Kuang, Peng ^a   Gao, Guanghui ^a   He, Yayi ^a   Fan, Lihong ^a   Fei, Ke ^a   Zhou, Caicun ^a,b   Schmit Bindert, Gerald ^d  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TONGJI UNIVERSITY   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Acquired resistance; EGFR TKI; MiR 21; Non small cell lung cancer; PDCD4; PI3K Akt; PTEN

Indexed keywords

GEFITINIB; LENTIVIRUS VECTOR; MICRORNA 21; MICRORNA 214; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION;

ACQUIRED RESISTANCE; EGFR-TKI; MIR-21; NON-SMALL CELL LUNG CANCER; PDCD4; PI3K/AKT; PTEN;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; PROTEIN KINASE INHIBITORS; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA-BINDING PROTEINS; TRANSGENES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892888388     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.11.003     Document Type: Article

References (47)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(January-February (1)):10-29. [Epub 2012 January 4]. 10.3322/caac.20138.
2. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12(8):735-742.
3. Ciuleanu T., Stelmakh L., Cicenas S., Miliauskas S., Grigorescu A.C., Hillenbach C., et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012, 13(March (3)):300-308. [Epub 2012 January 24].
4. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczésna A., Juhász E., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11(June (6)):521-529. [Epub 2010 May 20].
5. Wu Y.L., Kim J.H., Park K., Zaatar A., Klingelschmitt G., Ng C. Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study. Lung Cancer 2012, 77(August (2)):339-345. [Epub 2012 April 10].
6. Riely G.J., Politi K.A., Miller V.A., Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006, 12(24):7232-7241.
7. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
8. Engelman J.A., Janne P.A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008, 14(10):2895-2899.
9. Suda K., Murakami I., Katayama T., Tomizawa K., Osada H., Sekido Y., et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010, 16(November (22)):5489-5498. [Epub 2010 November 9].
10. Engels B.M., Hutvagner G. Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene 2006, 25:6163-6169.
11. Rosenfeld N., Aharonov R., Meiri E., Rosenwald S., Spector Y., Zepeniuk M., et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008, 26:462-469.
12. KentO A., Mendell J.T. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 2006, 25:6188-6196.
13. Hayashita Y., Osada H., Tatematsu Y., Yamada H., Yanagisawa K., Tomida S., et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005, 65:9628-9632.
14. Chen C.Z., Li L., Lodish H.F., Bart el D.P. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004, 303:83-86.
15. Brennecke J., Hipfner D.R., Stark A., Russell R.B., Cohen S.M. Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 2003, 113:25-36.
16. Chan J.A., Krichevsky A.M., Kosik K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005, 65:6029-6033.
17. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006, 103:2257-2261.
18. Li J., Huang H., Sun L., Yang M., Pan C., Chen W., et al. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res 2009, 15:3998-4008.
19. Xie Y., Todd N.W., Liu Z., Zhan M., Fang H., Peng H., et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 2010, 67:170-176.
20. Gao W., Yu Y., Cao H., Shen H., Li X., Pan S., et al. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 2010, 64:399-440.
21. Rossi S., Shimizu M., Barbarotto E., Nicoloso M.S., Dimitri F., Sampath D., et al. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 2010, 116:945-952.
22. Hwang J.H., Voortman J., Giovannetti E., Steinberg S.M., Leon L.G., Kim Y.T., et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS ONE 2010, 5:10630.
23. Giovannetti E., Funel N., Peters G.J., Del Chiaro M., Erozenci L.A., Vasile E., et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 2010, 70:4528-4538.
24. Shi G.H., Ye D.W., Yao X.D., Zhang S.L., Dai B., Zhang H.L., et al. Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin 2010, 31:867-873.
25. Shi L., Chen J., Yang J., Pan T., Zhang S., Wang Z. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res 2010, 1352:255-264.
26. Tomimaru Y., Eguchi H., Nagano H., Wada H., Tomokuni A., Kobayashi S., et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 2010, 103(10):1617-1626.
27. Wang Z.X., Lu B.B., Wang H., Cheng Z.X., Yin Y.M. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Arch Med Res 2011, 42(4):281-290.
28. Ren Y., Zhou X., Mei M., Yuan X.B., Han L., Wang G.X., et al. MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer 2010, 10:27.
29. Zhang J.G., Wang J.J., Zhao F., Liu Q., Jiang K., Yang G.H. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 2010, 411(11/12):846-852.
30. Bhatti I., Lee A., James V., Hall R.I., Lund J.N., Tufarelli C., et al. Knockdown of microRNA-21 inhibits proliferation and increases cell death by targeting programmed cell death 4 (PDCD4) in pancreatic ductal adenocarcinoma. J Gastrointest Surg 2011, 15(1):199-208.
31. Sheedy F.J., Palsson-McDermott E., Hennessy E.J., Martin C., O'Leary J.J., Ruan Q., et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010, 11(2):141-147.
32. Gaur A.B., Holbeck S.L., Colburn N.H., Israel M.A. Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. Neuro Oncol 2011, 13(6):580-590.
33. She Q.B., Solit D.B., Ye Q., O'Reilly K.E., Lobo J., Rosen N. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005, 8(4):287-297.
34. Sos M.L., Koker M., Weir B.A., Heynck S., Rabinovsky R., Zander T., et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009, 69(8):3256-3261.
35. Yamasaki F., Johansen M.J., Zhang D., Krishnamurthy S., Felix E., Bartholomeusz C., et al. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 2007, 67(12):5779-5788.
36. Ju L., Zhou C., Li W., Yan L. Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. J Cell Biochem 2010, 111(December (6)):1565-1574.
37. Jackman D., Pao W., Riely G.J., Engelman J.A., Kris M.G., Jänne P.A., et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010, 28(January (2)):357-360. [Epub 2009 November 30.49].
38. Chan J.A., Krichevsky A.M., Kosik K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005, 65:6029-6033.
39. Selcuklu S.D., Donoghue M.T., Spillane C. miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans 2009, 37:918-925.
40. Chang F., Lee J.T., Navolanic P.M., Steelman L.S., Shelton J.G., Blalock W.L., et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003, 17(3):590-603.
41. Kim S.M., Kim J.S., Kim J.H., Yun C.O., Kim E.M., Kim H.K., et al. Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells. Cancer Lett 2010, 296(2):150-159.
42. Hilliard A., Hilliard B., Zheng S.J., Sun H., Miwa T., Song W., et al. Translational regulation of autoimmune inflammation and lymphoma genesis by programmed cell death. J Immunol 2006, 177:8095-8102.
43. Jansen A.P., Camalier C.E., Colburn N.H. Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res 2005, 65:6034-6041.
44. Yang H.S., Matthews C.P., Clair T., Wang Q., Baker A.R., Li C.C., et al. Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion. Mol Cell Biol 2006, 26:1297-1306.
45. Cmarik J.L., Min H., Hegamyer G., Zhan S., Kulesz-Martin M., Yoshinaga H., et al. Differentially expressed protein Pdcd4 inhibits tumor promoterinduced neoplastic transformation. Proc Natl Acad Sci USA 1999, 96:14037-14042.
46. Yang H.S., Knies J.L., Stark C., Colburn N.H. Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene 2003, 22:3712-3720.
47. Shiota M., Izumi H., Tanimoto A., Takahashi M., Miyamoto N., Kashiwagi E., et al. Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res 2009, 69:3148-3156.